Expert Interview
A second look - Q2 update: Discussing the expanded label for Amvuttra, and commercial outlook for Amvuttra, Vyndaqel and Attruby in Transthyretin amyloid cardiomyopathy (ATTR-CM) with an academic cardiologist
Ticker(s): BBIO, ALNY, PFEInstitution: Washington University St. Louis
- Director of the Cardio-Oncology Center of Excellence and Co-Director of the Amyloid Center of Excellence at the Washington University St. Louis.
- Treats ~ 10 ATTR-CM patients monthly.
- Clinical and Research interests include better characterizing and understanding cardiovascular disease associated with cancer treatment, and diagnosis and managment of cardiac amyloidosis
How do you view Attruby compared to Vyndaqel?
Added By: wilson_adminHow do you view Amvuttra versus the oral options?
Added By: wilson_adminWhat are your thoughts on some of the investigational therapies, i.e. eplontersen and Nex-Z
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
